Jump to content

Tizanidine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
→top: update rank
Line 15: Line 15:
| MedlinePlus = a601121
| MedlinePlus = a601121
| DailyMedID = Tizanidine
| DailyMedID = Tizanidine
| pregnancy_US = C
| pregnancy_category =
| pregnancy_category =
| legal_US = Rx-only
| legal_US = Rx-only
Line 67: Line 66:


<!-- History and culture -->
<!-- History and culture -->
Tizanidine was approved for medical use in the United States in 1996.<ref name=AHFS2019/> It is available as a [[generic medication]].<ref name=BNF76/> In 2018, it was the 86th most commonly prescribed medication in the United States, with more than 8{{nbsp}}million prescriptions.<ref>{{cite web |title=The Top 300 of 2021 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=ClinCalc |access-date=18 February 2021}}</ref><ref>{{cite web | title=Tizanidine - Drug Usage Statistics | website=ClinCalc | url=https://clincalc.com/DrugStats/Drugs/Tizanidine | access-date=18 February 2021}}</ref>
Tizanidine was approved for medical use in the United States in 1996.<ref name=AHFS2019/> It is available as a [[generic medication]].<ref name=BNF76/> In 2019, it was the 92nd most commonly prescribed medication in the United States, with more than 8{{nbsp}}million prescriptions.<ref>{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=ClinCalc |access-date=16 October 2021}}</ref><ref>{{cite web | title=Tizanidine - Drug Usage Statistics | website=ClinCalc | url=https://clincalc.com/DrugStats/Drugs/Tizanidine | access-date=16 October 2021}}</ref>


==Medical uses==
==Medical uses==

Revision as of 04:31, 19 October 2021

Tizanidine
Clinical data
Pronunciation/taɪˈzænɪdiːn/ tye-ZAN-i-deen
Trade namesZanaflex, Sirdalud, and others
Other names4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-8-thia-7,9-diazabicyclo[4.3.0]nona-2,4,6,9-tetraen-5-amine
AHFS/Drugs.comMonograph
MedlinePlusa601121
License data
Routes of
administration		By mouth (tablets, capsules)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability~40%[1]
Protein binding~30%
MetabolismLiver (CYP1A2, 95%)
Elimination half-life2.54 hours (tizanidine), 20–40 hours (inactive metabolites)[1]
ExcretionUrine (60%), feces (20%)
Identifiers
  • 5-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)benzo[c] [1,2,5]thiadiazol-4-amine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.125.400 Edit this at Wikidata
Chemical and physical data
FormulaC9H8ClN5S
Molar mass253.71 g·mol−1
3D model (JSmol)
  • Clc1ccc3nsnc3c1NC/2=N/CCN\2
  • InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13) checkY
  • Key:XFYDIVBRZNQMJC-UHFFFAOYSA-N checkY
  (verify)

Tizanidine, sold under the brand name Zanaflex among others, is a medication that is used to treat muscle spasticity due to spinal cord injury or multiple sclerosis.[2] Effectiveness appears similar to baclofen or diazepam.[3] It is taken by mouth.[4]

Common side effects include dry mouth, sleepiness, weakness, and dizziness.[4] Serious side effects may include low blood pressure, liver problems, psychosis, and QT prolongation.[4] It is unclear if use in pregnancy and breastfeeding is safe.[5] It is an α2-adrenergic agonist and how it works is not entirely clear.[4]

Tizanidine was approved for medical use in the United States in 1996.[4] It is available as a generic medication.[2] In 2019, it was the 92nd most commonly prescribed medication in the United States, with more than 8 million prescriptions.[6][7]

Medical uses

Tizanidine has been found to be as effective as other antispasmodic drugs and is more tolerable than baclofen and diazepam.[3]

Side effects

Side effects include dizziness, drowsiness, weakness, nervousness, confusion, hallucinations, strange dreams, depression, vomiting, dry mouth, constipation, diarrhea, stomach pain, heartburn, increased muscle spasms, back pain, rash, sweating, and a tingling sensation in the arms, legs, hands, and feet.[8]

Interactions

Concomitant use of tizanidine and moderate or potent CYP1A2 inhibitors (such as zileuton, certain antiarrhythmics (amiodarone, mexiletine, propafenone, verapamil), cimetidine, famotidine, aciclovir, ticlopidine and oral contraceptives) is contraindicated. Concomitant use of tizanidine with fluvoxamine, a potent CYP1A2 inhibitor in humans, resulted in a 33-fold increase in the tizanidine AUC (plasma drug concentration-time curve).[1] For this reason both fluvoxamine and tizanidine should not be taken at the same time. Fluoroquinolone antibiotics such as moxifloxacin, levofloxacin, and ciprofloxacin should also be avoided due to an increased serum concentration of tizanidine when administered concomitantly.[9] Tizanidine has the potential to interact with other central nervous system depressants. Alcohol should be avoided, particularly as it can upset the stomach. The CNS-depressant effects of tizanidine and alcohol are additive.[1] Caution with the following interactions:[10][11][12]

Pharmacology

Tizanidine is an α2 receptor agonist closely related to clonidine. It has approximately one tenth to one fifteenth of the pressure lowering effect of clonidine. The relation between the α2 receptor agonism and the spasmolytic action is still not fully understood.[13]

Route of administration

Tizanidine is available as a tablet or capsule. Capsules may be opened and sprinkled on food. However, this may change the absorption of the medication compared to taking the capsule whole.[14]

Chemistry

It has a volume of distribution of 2.4 L/kg following intravenous administration.[1]

References

  1. ^ a b c d e "Zanaflex (tizanidine hydrochloride) Capsules and Tablets for Oral Use. Full Prescribing Information" (PDF). Acorda Therapeutics Inc. Ardsley, NY 10502. Retrieved 1 September 2016.
  2. ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1094. ISBN 9780857113382.
  3. ^ a b Kamen L, Henney HR, Runyan JD (February 2008). "A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury". Current Medical Research and Opinion. 24 (2): 425–39. doi:10.1185/030079908X261113. PMID 18167175. S2CID 73086671.
  4. ^ a b c d e "Tizanidine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
  5. ^ "Tizanidine Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
  6. ^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.
  7. ^ "Tizanidine - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.
  8. ^ pmhdev. "Page not available". PubMed Health. Archived from the original on 11 November 2012. Retrieved 4 September 2017.
  9. ^ "Tizanidine Uses, Dosage, Side Effects – Drugs.com". drugs.com. Retrieved 4 September 2017.
  10. ^ NHS Wales (2011). "Tizanidine (Zanaflex) Gwent Primary Care Prescribing Guidance" (PDF). Aneurin Bevan University Health Board.
  11. ^ "Tizanidine package leaflet: Information for the user" (PDF). Medicines and Healthcare products Regulatory Agency (UK). 2016.
  12. ^ "Zanaflex (tizanidine hydrochloride) dose, indications, adverse effects, interactions... from PDR.net". www.pdr.net. Retrieved 16 September 2018.
  13. ^ Katzung, Bertram G. (30 November 2017). Basic & clinical pharmacology. Katzung, Bertram G. (Fourteenth ed.). New York. p. 487. ISBN 9781259641152. OCLC 1015240036.{{cite book}}: CS1 maint: location missing publisher (link)
  14. ^ "Tizanidine: MedlinePlus Drug Information". medlineplus.gov. U.S. National Library of Medicine. Retrieved 29 October 2019.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Tizanidine&oldid=1050657756"